Christophe Weber describes Takeda's global perspective on R&D and business development
- blonca9
- Jan 8, 2024
- 1 min read
Takeda's CEO talks about the $4B+ Nimbus acquisition, recent approvals, and what's ahead for the company in 2024.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
bottom of page